Mary Jenkins
Associate Director, Investor Relations and Corporate Communications
Replay available
Sarepta Therapeutics, Inc. (SRPT) Q4 2024 Earnings Call
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Q4 2024 earnings conference call, held 2025-02-26. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Doug Ingram
President and CEO
Dallin Murray
Chief Customer Officer
Dr. Louise Rodino-Klapack
Head of R&D and Chief Scientific Officer
Ian Estepan
Chief Financial Officer
Tuzine Ahmad
Bank of America Securities Analyst
Ellie Merle
UBS Analyst
Jenna Wayne
Barclays Analyst
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Sarepta Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.291 -- 00:00:02.593 and full year 2024 00:00:02.593 -- 00:00:08.118 financial results conference call. As a reminder, today's program is being recorded. 00:00:08.118 -- 00:00:12.882 At this time, I'd like to turn the call over to Mary Jenkins, Associate Director, Investor 00:00:12.882 -- 00:00:17.825 Relations and Corporate Communications. Please go ahead. 00:00:17.947 -- 00:00:20.329 Thank you, Lisa, and thank you all for joining today's call. 00:00:20.329 -- 00:00:23.892 Earlier this afternoon, we released our financial results for the fourth quarter and 00:00:23.892 -- 00:00:28.797 full year 2024. The press release, slides, and supplementary information are available 00:00:28.797 -- 00:00:32.020 on the investor section of our website at Sarepta.com. 00:00:32.020 -- 00:00:35.402 Our 10-K will be filed with the SEC later this week. 00:00:35.402 -- 00:00:40.346 Joining us on the call today are Doug Ingram, Ian Estepan, Dallin Murray, and Dr. 00:00:40.346 -- 00:00:45.130 Louise Rodino-Klapak. After our formal remarks, we'll open the call for Q&A. 00:00:45.130 -- 00:00:49.133 I'd like to note that during this call, we were making a number of forward-looking statements. 00:00:49.133 -- 00:00:52.957 Please refer to slide two on the webcast, which contains our forward-looking statements. 00:00:52.957 -- 00:00:56.858 These forward-looking statements involve risks and uncertainties, many of which are beyond 00:00:56.858 -- 00:01:01.000 surreptitious control. Actual results could materially differ from these forward-looking 00:01:01.000 -- 00:01:06.141 statements, and any such risks can materially and adversely affect 00:01:06.141 -- 00:01:10.683 the business. The results of operations and trading prices for surreptitious common stock. 00:01:10.683 -- 00:01:1...